ClinicalTrialsFinder

Potentially Resectable Clinical Trials in Shanghai

1 recruitingShanghai, China

Showing 1–1 of 1 trials

Recruiting
Phase 2

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

EGFR-mutant Non-small Cell Lung CancerPotentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China36 enrolled1 locationNCT07323056